At the news
? NEUTRALIMPACT 4/10 8-K filed Feb 26, 2026 at 07:51 ET
vTv Therapeutics released an investor presentation disclosing that its lead asset, Cadisegliatin, is in Phase 3 development for type 1 diabetes, with topline data expected in the second half of 2026. The company highlighted a strong balance sheet with $118.5 million in cash, providing runway past the data readout. No new financial guidance or clinical results were provided.
- Cadisegliatin is in Phase 3 development for type 1 diabetes with topline CATT1 data targeted for 2H 2026
- Company has $98.5M cash as of 9/30/2025 plus $20.0M received on 2/2/2026, totaling $118.5M
- Cadisegliatin has FDA Breakthrough Therapy Designation for treatment of T1D
- Presentation contains forward-looking statements about future operations and financial performance
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access